Tag:

Abraxane

Latest Headlines

Latest Headlines

Bristol-Myers, Celgene pair an immuno-oncology star with a rising chemotherapy

Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.

Celgene raises earnings forecast third time

Celgene CFO Jacqualyn Fouse recently noted the markets have been rewarding the biotech for plainly explaining how its pieces fit together to reward investors. That comfort with the company came into play again today when its shares were unfazed even though it reported lower net income on higher expenses. Investors were placated when the Summit, NJ-based company raised its earnings forecast for the year for the third time.

Celgene's Abraxane approved for first-line treatment of pancreatic cancer

The FDA today approved Celgene's Abraxane for pancreatic cancer, an approval that provides some hope for extending the lives of patients with the aggressive cancer. It should also significantly extend the earnings power of the drug, which is already approved for breast and lung cancers.

Celgene's Abraxane shows promise in pancreatic cancer

A drug that Celgene ($CELG) acquired in its $2.9 billion acquisition of  Abraxis BioScience in 2010 is showing promise against the notoriously hard-to-treat p ancreatic cancer. 

Celgene keeps biotech spotlight with sanguine Abraxane data in pancreatic cancer

Celgene CEO Bob Hugin is leading a push to rapidly grow the major drugmaker, keeping the company atop lists of go-to partners among biotechs.

Celgene chief Hugin wows J.P. Morgan with blockbuster plans for 2013

Celgene captured the center ring at the J.P. Morgan conference on its opening day Monday. Company CEO Bob Hugin boldly mapped out a 5-year plan to double sales and highlighted upbeat Phase III data on its psoriasis drug apremilast that he believes will set the stage for regulatory approval on both sides of the Atlantic.

Celgene shares jump on Abraxane pancreatic cancer results

The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.Analysts greeted the data with some impressive sales projections.

Celgene's Abraxane boosts survival in pancreatic cancer

They're popping corks at Celgene ($CELG) headquarters. The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.

Celgene's Abraxane doubles PFS for melanoma patients in PhIII

Researchers say the data reflect a positive trend for overall survival.

New FDA lung cancer OK for Celgene's Abraxane should boost sales

When Celgene bought out Abraxis two years ago for an eye-popping $2.9 billion, it set out to prove that it could do a better job selling the drug for breast cancer while expanding the drug's use with additional approvals. Today it delivered on part of that promise with an FDA OK on first-line use for advanced or metastatic non-small cell lung cancer.